MediciNova Inc is a biopharmaceutical company. The company acquires and develops small-molecule therapeutics for the treatment of diseases with unmet medical needs with a specific focus on the U.S. market. Its products portfolio includes therapeutics such as MN-001, MN-166, MN-221 etc. The firm's current strategy is to focus its development activities on therapeutics for neurological disorders and fibrotic diseases.
相关临床试验
17
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
11.8%
已完成
14
82.3%
终止
1
5.9%
暂无批准数据
- After the 2022 reset, biotech capital has returned through 2025-2026, but with stricter conditions favoring late-stage, data-rich companies over early-stage promise. - Follow-on equity issuance reached roughly $56 billion in 2025, with nearly 90% of life sciences IPO issuers in Phase 2 or later, signaling a market that demands de-risked assets. - Cross-border out-licensing from Greater China hit approximately $138 billion in 2025, nearly ten times the 2021 figure, with China now accounting for roughly 30% of the global clinical pipeline. - Neuroscience and rare disease are emerging as compelling value creation opportunities, supported by biomarker advances, regulatory flexibility including accelerated approval pathways, and validated brain-penetrant mechanisms.
- MediciNova received a Notice of Allowance from the USPTO for a patent covering ibudilast (MN-166) combined with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment. - The allowed claims encompass multiple anti-PD-1 antibodies and broad treatment parameters including dosing regimen, route of administration, dose levels, and duration of therapy. - Once issued, the patent is expected to expire no earlier than September 2042, strengthening the company's intellectual property position in oncology. - Ibudilast is a PDE4 and inflammatory cytokine inhibitor currently in late-stage development for ALS, progressive MS, DCM, and glioblastoma.
- MediciNova has completed enrollment in the Phase 2b/3 COMBAT-ALS trial of MN-166 (ibudilast) in amyotrophic lateral sclerosis, with 234 participants across the US and Canada and topline data expected by end of 2026. - MN-166 is a CNS-penetrant small molecule with a multi-target mechanism including MIF, PDE, and TLR4 inhibition, holding both Orphan Drug Designation and Fast Track status from the US FDA. - The NIH-funded SEA-NOBI-ALS study targeting late-stage ALS patients has activated 12 US sites and enrolled 100 of 200 planned participants as of January 2026, supported by $22 million in funding. - MN-166's multi-indication strategy spans degenerative cervical myelopathy, long COVID, substance use disorders, and chemotherapy-induced peripheral neuropathy, with US patents securing market exclusivity until at least 2040.
- MediciNova announced completion of last patient last visit in its Phase 2 MN-001-NATG-202 trial evaluating tipelukast for hypertriglyceridemia and NAFLD associated with type 2 diabetes. - The randomized, double-blind, placebo-controlled study enrolled patients to receive either 500 mg/day tipelukast or placebo for 24 weeks with co-primary endpoints measuring liver fat content and fasting triglycerides. - Tipelukast demonstrates multiple mechanisms of action including leukotriene receptor antagonism and phosphodiesterase inhibition, targeting both inflammatory and fibrotic pathways in liver disease. - Top-line results from the trial are expected in the third quarter of 2026, potentially advancing treatment options for metabolic complications in diabetic patients.
- Researchers at the Spanish National Cancer Research Centre identified macrophage migration inhibitory factor (MIF)-mediated reprogramming of CD74-positive microglia and macrophages as a central vulnerability in brain metastasis. - The study published in Cancer Research demonstrates that MediciNova's ibudilast can effectively block MIF-CD74 signaling and suppress brain metastasis growth in preclinical models. - Brain metastases develop in up to 30% of patients with advanced solid tumors and represent a significant unmet medical need with limited treatment options. - MediciNova plans to collaborate with CNIO researchers on future clinical studies targeting patients with solid tumors that have metastasized to the brain.
- MediciNova appointed Dr. Christopher Breder, a distinguished physician-scientist with over two decades of FDA and pharmaceutical industry experience, as Clinical and Regulatory Advisor. - Dr. Breder brings extensive expertise in neurological drug approvals, having played key roles in FDA reviews for ALS, Myasthenia Gravis, and Duchenne Muscular Dystrophy treatments. - The appointment strengthens MediciNova's regulatory strategy as the company advances its Phase 3 ALS program with MN-166 (ibudilast) and multiple other neurological indications.
- CASI Pharmaceuticals' stock surged 57.2% to $2.028 after the FDA cleared its IND application for CID-103, an anti-CD38 monoclonal antibody targeting kidney transplant rejection. - The Phase 1 trial will evaluate CID-103 in adults with active and chronic active renal allograft antibody-mediated rejection, addressing an $800 million to $1.2 billion unmet medical need. - Trading volume spiked 2,043% to 62.9 million shares, indicating strong institutional interest in the regulatory milestone. - The FDA clearance positions CID-103 as a potential best-in-class therapy for antibody-mediated rejection, where current treatments face safety limitations.
- MediciNova has signed a 36-month Standby Equity Purchase Agreement with Yorkville Advisors for up to $30 million to support R&D programs and general corporate activities. - The agreement provides flexible access to capital at 97% of market price without issuing warrants, allowing the company to take advantage of favorable market conditions. - Proceeds will advance development of MN-166 (ibudilast) for neurological disorders including ALS and progressive MS, and MN-001 (tipelukast) for fibrotic diseases like NAFLD. - CEO Dr. Yuichi Iwaki stated the company's current cash position allows continued operations while the SEPA provides additional flexibility for R&D initiatives and strategic opportunities.
- MediciNova is developing MN-166 (ibudilast) for multiple neurological disorders including ALS, progressive multiple sclerosis, and glioblastoma through various clinical trial approaches. - The company's MN-001 (tipelukast) targets fibrotic and metabolic disorders such as NAFLD and hypertriglyceridemia using novel anti-inflammatory and anti-fibrotic mechanisms. - MediciNova plans to advance its pipeline through investigator-sponsored trials, government grants, and strategic alliances to support clinical development of both lead programs.
- MediciNova's Phase 2/3 COMBAT-ALS trial for MN-166 (ibudilast) is down to single-digit enrollment requirements, marking a critical milestone in ALS treatment development. - The company's MN-001 (tipelukast) Phase 2 trial for dyslipidemia and fatty liver disease in type 2 diabetes patients needs only two more subjects to complete enrollment. - Top-line data from the COMBAT-ALS trial is anticipated by the end of next year, with regulatory discussions with the FDA being actively prepared. - A parallel $22 million NIH-funded Expanded Access Program is steadily enrolling patients, demonstrating significant interest from the ALS community.
